Evolus (EOLS) News Today $11.39 -0.83 (-6.79%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$11.35 -0.04 (-0.35%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Evolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 6,251 SharesEvolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.March 29, 2025 | marketbeat.comEvolus to Participate in The Needham 24th Annual Virtual Healthcare ConferenceMarch 25, 2025 | finance.yahoo.comEvolus (NASDAQ:EOLS) Trading Down 2.4% - Should You Sell?Evolus (NASDAQ:EOLS) Stock Price Down 2.4% - What's Next?March 25, 2025 | marketbeat.comInvesting in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gainMarch 23, 2025 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) CMO Sells $60,147.36 in StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the transaction, the chief marketing officer now owns 95,671 shares of the company's stock, valued at approximately $1,268,597.46. This trade represents a 4.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.March 21, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 8,996 SharesEvolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 8,996 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $119,286.96. Following the completion of the transaction, the chief financial officer now owns 173,583 shares in the company, valued at $2,301,710.58. This represents a 4.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 21, 2025 | marketbeat.comRui Avelar Sells 27,904 Shares of Evolus, Inc. (NASDAQ:EOLS) StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) insider Rui Avelar sold 27,904 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the sale, the insider now owns 362,467 shares of the company's stock, valued at $4,806,312.42. This trade represents a 7.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.March 21, 2025 | marketbeat.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | businesswire.comEvolus, Inc. (NASDAQ:EOLS) CMO Sells $60,147.36 in StockMarch 21, 2025 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) Director Sells $167,415.12 in StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Karah Herdman Parschauer sold 12,888 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares in the company, valued at approximately $418,057.17. This represents a 28.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 15, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Director Karah Herdman Parschauer Sells 12,888 SharesMarch 15, 2025 | insidertrades.comBender Robert & Associates Invests $277,000 in Evolus, Inc. (NASDAQ:EOLS)Bender Robert & Associates purchased a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,070 shares of the company's stock, valued at approximately $277,00March 12, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Trading Down 9.6% - What's Next?Evolus (NASDAQ:EOLS) Shares Down 9.6% - Here's What HappenedMarch 11, 2025 | marketbeat.comEssex Investment Management Co. LLC Has $2.02 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)Essex Investment Management Co. LLC decreased its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 38.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 182,503 shares of the company's stock after seMarch 10, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Evolus FY2025 Earnings?Evolus, Inc. (NASDAQ:EOLS - Free Report) - Research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of Evolus in a research note issued on Wednesday, March 5th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.23) per share for thMarch 10, 2025 | marketbeat.comEvolus' (EOLS) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday.March 6, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Wednesday.March 6, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Price Target Raised to $25.00Barclays increased their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday.March 6, 2025 | marketbeat.comEvolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market UncertaintyMarch 6, 2025 | tipranks.comEvolus (NASDAQ:EOLS) Issues Earnings Results, Misses Estimates By $0.09 EPSEvolus (NASDAQ:EOLS - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.09). Evolus had a negative return on equity of 847.60% and a negative net margin of 22.33%.March 5, 2025 | marketbeat.comEvolus price target raised to $25 from $22 at BarclaysMarch 5, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and Evolus (EOLS)March 5, 2025 | markets.businessinsider.comEvolus, Inc. (EOLS) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | seekingalpha.comEvolus, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 4, 2025 | seekingalpha.comEvolus reports Q4 EPS (11c) vs (21c) last yearMarch 4, 2025 | markets.businessinsider.comEvolus sees FY25 revenue $345M-$355M, consensus $351.94MMarch 4, 2025 | markets.businessinsider.comEvolus posts quarterly profit on strong sales of cosmetic injectionMarch 4, 2025 | reuters.comEvolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 GuidanceMarch 4, 2025 | businesswire.comLos Angeles Capital Management LLC Sells 18,817 Shares of Evolus, Inc. (NASDAQ:EOLS)Los Angeles Capital Management LLC decreased its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 24.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,623 shares of the company's stock afteMarch 3, 2025 | marketbeat.comIs Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now?March 2, 2025 | insidermonkey.comEvolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor ConferencesFebruary 27, 2025 | businesswire.comEvolus (EOLS) Expected to Announce Quarterly Earnings on TuesdayEvolus (NASDAQ:EOLS) will be releasing earnings after the market closes on Tuesday, March 4. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=667503)February 25, 2025 | marketbeat.comEvolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness SummitFebruary 20, 2025 | finance.yahoo.comRice Hall James & Associates LLC Has $10.47 Million Stake in Evolus, Inc. (NASDAQ:EOLS)Rice Hall James & Associates LLC boosted its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 948,281 shares of the company's stocFebruary 18, 2025 | marketbeat.comEvolus's SWOT analysis: FDA nod for filler boosts stock outlookFebruary 17, 2025 | msn.comHC Wainwright Reiterates "Buy" Rating for Evolus (NASDAQ:EOLS)HC Wainwright restated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Friday.February 15, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Stock Price Up 15.3% - What's Next?Evolus (NASDAQ:EOLS) Stock Price Up 15.3% - Here's WhyFebruary 14, 2025 | marketbeat.comLegato Capital Management LLC Sells 43,769 Shares of Evolus, Inc. (NASDAQ:EOLS)Legato Capital Management LLC lessened its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 40.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 64,778 shares of the company's stock after selling 43,769 shares duringFebruary 14, 2025 | marketbeat.comEvolus Gets FDA Approval for Two Injectable Hyaluronic Acid GelsFebruary 13, 2025 | marketwatch.comEvolus trading halted, news pendingFebruary 13, 2025 | markets.businessinsider.comEvolus announces FDA approval of Evolysse productsFebruary 13, 2025 | markets.businessinsider.comEvolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid GelsFebruary 13, 2025 | finance.yahoo.comEvolus Announces FDA Approval of Evolysseâ„¢ Form and Evolysseâ„¢ Smooth Injectable Hyaluronic Acid GelsFebruary 13, 2025 | businesswire.comUS FDA approves Evolus' anti-wrinkle gelsFebruary 13, 2025 | reuters.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | businesswire.comEvolus (NASDAQ:EOLS) Shares Down 6.5% - Should You Sell?Evolus (NASDAQ:EOLS) Shares Down 6.5% - Here's WhyFebruary 3, 2025 | marketbeat.comBarclays Sticks to Their Buy Rating for Evolus (EOLS)January 27, 2025 | markets.businessinsider.comEvolus price target raised to $22 from $20 at BarclaysJanuary 27, 2025 | markets.businessinsider.comEvolus (NASDAQ:EOLS) Given New $22.00 Price Target at BarclaysBarclays lifted their price objective on shares of Evolus from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Monday.January 27, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for Evolus EarningsEvolus, Inc. (NASDAQ:EOLS - Free Report) - HC Wainwright upped their Q4 2024 EPS estimates for shares of Evolus in a research note issued on Wednesday, January 22nd. HC Wainwright analyst D. Tsao now expects that the company will earn $0.00 per share for the quarter, up from their prior estimateJanuary 24, 2025 | marketbeat.com Remove Ads Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Media Mentions By Week EOLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EOLS News Sentiment▼0.490.61▲Average Medical News Sentiment EOLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EOLS Articles This Week▼24▲EOLS Articles Average Week Remove Ads Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Scholar Rock News Today Protagonist Therapeutics News Today Catalyst Pharmaceuticals News Today Alvotech News Today Merus News Today Immunovant News Today Metsera News Today MorphoSys News Today ACADIA Pharmaceuticals News Today Apellis Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EOLS) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EOLS Stock Free EOLS Stock Alerts